To evaluate the long-term effectiveness, safety, and tolerability of erenumab in a real-world migraine population, looking for putative predictors of responsiveness.
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study / Barbanti, P., Aurilia, C., Cevoli, S., Egeo, G., Fofi, L., Messina, R., Salerno, A., Torelli, P., Albanese, M., Carnevale, A., Bono, F., D'Amico, D., Filippi, M., Altamura, C., Vernieri, F.. - In: HEADACHE. - ISSN 0017-8748. - 6:(2021), pp. 1351-1363. [10.1111/head.14194]
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
Messina, Roberta;Filippi, Massimo;
2021-01-01
Abstract
To evaluate the long-term effectiveness, safety, and tolerability of erenumab in a real-world migraine population, looking for putative predictors of responsiveness.| File | Dimensione | Formato | |
|---|---|---|---|
|
Headache 61_1351.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Tutti i diritti riservati
Dimensione
630.08 kB
Formato
Adobe PDF
|
630.08 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
